Skip to main content

Advertisement

SpringerLink
Log in

Uveitic Macular Edema: Treatment Update

  • Therapies in Age-Related Macular Degeneration (R. Goldhardt,Section Editor)
  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

Abstract

The aim of this review is to summarize recent developments in the treatment of uveitic macular edema (ME). ME represent a major cause of visual loss in uveitis and adequate management is crucial for the maintenance of useful vision in patients with chronic uveitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. Jabs DA. Epidemiology of uveitis. Ophthal Epidemiol. 2008;15:283–4.

    Article  Google Scholar 

  2. • Ossewaarde-van Norel A, Rothova A. Clinical review: update on treatment of inflammatory macular edema. Ocular Immunol Inflamm. 2011;19:75–83. They propose an algorithm for the treatment of uveitic macular edema pointing out the individual risk-benefit ratio when systemic immunosuppressive therapy is used.

  3. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574–9 e1.

  4. •• Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11:29–38. Highlights the current understanding of pathophysiology and immunology of uveitic macular edema.

  5. Dick AD. The treatment of chronic uveitic macular oedema. Br J Ophthalmol. 1994;78:1–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rothova A. Medical treatment of cystoid macular edema. Ocular Immunol Inflamm. 2002;10:239–46.

    Article  Google Scholar 

  7. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22:1133–40.

    Article  CAS  PubMed  Google Scholar 

  8. van Haeringen NJ, van Sorge AA, Core-Bodelier VMC. Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen. J Ocul Pharmacol. 2000;16:353–61.

    Article  Google Scholar 

  9. Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. 2005;140:1096–105.

    Article  PubMed  Google Scholar 

  10. •• van Kooij B, Probst K, Fijnheer R, Roest M, de Loos W, Rothova A. Risk factors for cystoid macular oedema in patients with uveitis. Eye (Lond). 2008;22:256–60. Retrospective cross-sectional study evaluating ophthalmologic and systemic factors associated with uveitic macular edema.

  11. Thorne JE, Daniel E, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008;145:841–6.

    Article  PubMed  PubMed Central  Google Scholar 

  12. • Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006;113:1446–9. Cross-sectional study that investigated causes of decrease in visual acuity in patients with uveitis.

  13. de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452–70.

    Article  PubMed  Google Scholar 

  14. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina. 2010;30:260–6.

    Article  PubMed  Google Scholar 

  15. Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother. 2009;10:2379–85.

    Article  CAS  PubMed  Google Scholar 

  16. Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010;88:896–900.

    Article  CAS  PubMed  Google Scholar 

  17. Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology. 2011;118:2120–7.

    Article  PubMed  Google Scholar 

  18. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3:147–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55:108–33.

    Article  PubMed  Google Scholar 

  20. Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:1801–6.

    Article  CAS  PubMed  Google Scholar 

  21. Angunawela RI, Heatley CJ, Williamson TH, et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand. 2005;83:595–9.

    Article  CAS  PubMed  Google Scholar 

  22. Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16:217–23.

    Article  PubMed  Google Scholar 

  23. Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011;152(441–8):e2.

    PubMed  Google Scholar 

  24. Jea SY, Byon IS, Oum BS. Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis. Korean J Ophthalmol. 2006;20:99–103.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2009;25:159–62.

    Article  CAS  PubMed  Google Scholar 

  26. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–49.

    Article  PubMed  Google Scholar 

  27. Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner RD. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009;116:455–60.

    Article  PubMed  Google Scholar 

  28. Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114:1912–8.

    Article  PubMed  Google Scholar 

  29. •• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118:1916–26. Randomized controlled parallel superiority trial comparing systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis by MUST.

  30. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000;41:3569–75.

    CAS  PubMed  Google Scholar 

  31. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126:1191–201.

    Article  PubMed  Google Scholar 

  32. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117:567–75, 75 e1.

  33. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192–8.

    Article  PubMed  Google Scholar 

  34. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–7.

    Article  PubMed  Google Scholar 

  35. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28:351–66.

    Article  CAS  PubMed  Google Scholar 

  36. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–53.

    Article  PubMed  Google Scholar 

  37. • Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309–17. This was a 6-month randomized study using a single dexamethasone DDS treatment in patients with persistent macular edema.

  38. Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29:501–7.

    Article  CAS  PubMed  Google Scholar 

  39. Venkatesh P, Abhas Z, Garg S, Vohra R. Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Archive Clin Exp Ophthal. 2007;245:59–67.

    Article  CAS  Google Scholar 

  40. •• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492–513. Recommendations of a 12-person panel of physicians with expertise in ophthalmic, pediatric and rheumatologic disease for the use of immunosuppressive therapy in patient care.

  41. •• Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996;103:1054–62; discussion 62–3. This was a randomized cross-over trial including 37 patients comparing acetazolamide versus placebo. They received a 4-week course of either acetazolamide or placebo followed by a 4-week washout period.

  42. Farber MD, Lam S, Tessler HH, Jennings TJ, Cross A, Rusin MM. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study. Br J Ophthalmol. 1994;78:4–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Lashay AR, Rahimi A, Chams H, et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet’s disease. Eye (Lond). 2003;17:762–6.

    Article  CAS  Google Scholar 

  44. Kafkala C, Choi JY, Choopong P, Foster CS. Octreotide as a treatment for uveitic cystoid macular edema. Arch Ophthalmol. 2006;124:1353–5.

    Article  PubMed  Google Scholar 

  45. Missotten T, van Laar JA, van der Loos TL, et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol. 2007;144:838–43.

    Article  CAS  PubMed  Google Scholar 

  46. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14:285–94.

    PubMed  Google Scholar 

  47. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist. 2007;12:443–50.

    Article  CAS  PubMed  Google Scholar 

  48. Karim R, Tang B. Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol. 2010;4:493–517.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest. 2003;112:1655–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. • Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 2009;23:1812–8. In one group they measured intravitreal VEGF levels in uveitis patients and controls and in a second group they treated macular edema with anti-VEGF. If no response, they switched to triamcinolone. VEGF levels in uveitic patients were similar to patients with AMD. Anti-VEGF had a positive effect in uveitic macular edema when there wasn’t an extensive breakdown of the outer blood-retinal barrier or extensive leakage.

  51. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol. 2009;19:622–9.

    PubMed  Google Scholar 

  52. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28:41–5.

    Article  PubMed  Google Scholar 

  53. Al-Dhibi H, Hamade IH, Al-Halafi A, et al. The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema. J Ophthalmol. 2014;2014:729465.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Okada AA, Keino H, Watanabe T, Taki W, Hayakawa R. Recurrence of acute anterior inflammation after intravitreal injection of bevacizumab in uveitis. Jpn J Ophthalmol. 2009;53:182–4.

    Article  PubMed  Google Scholar 

  55. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29:313–8.

    Article  PubMed  Google Scholar 

  57. Goldberg RA, Shah CP, Wiegand TW, Heier JS. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol. 2014;158(733–7):e1.

    Article  PubMed  Google Scholar 

  58. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117:1612–6.

    Article  PubMed  Google Scholar 

  59. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004;49:470–90.

    Article  PubMed  Google Scholar 

  60. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–50.

    Article  CAS  PubMed  Google Scholar 

  61. Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol. 2009;29:127–33.

    Article  PubMed  Google Scholar 

  62. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481–6.

    Article  PubMed  Google Scholar 

  63. Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol. 2009;3:559–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–91.

    Article  PubMed  Google Scholar 

  65. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55–61.

    Article  CAS  PubMed  Google Scholar 

  66. Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–13.

    Article  CAS  PubMed  Google Scholar 

  67. Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17:403–14.

    Article  CAS  PubMed  Google Scholar 

  68. Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351–61.

    Article  CAS  PubMed  Google Scholar 

  69. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116:797–801.

    Article  PubMed  Google Scholar 

  70. Wang J, Ibrahim M, Turkcuoglu P, et al. Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocul Immunol Inflamm. 2010;18:395–8.

    Article  PubMed  Google Scholar 

  71. Nussenblatt RB, Kim J, Thompson DJ, et al. Vitamin E in the treatment of uveitis-associated macular edema. Am J Ophthalmol. 2006;141:193–4.

    Article  CAS  PubMed  Google Scholar 

  72. Suttorp-Schulten MS, Feron E, Postema F, Kijlstra A, Rothova A. Macular grid laser photocoagulation in uveitis. Br J Ophthalmol. 1995;79:821–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm. 2007;15:71–9.

    Article  PubMed  Google Scholar 

  74. Gutfleisch M, Spital G, Mingels A, Pauleikhoff D, Lommatzsch A, Heiligenhaus A. Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol. 2007;91:345–8.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Schaal S, Tezel TH, Kaplan HJ. Surgical intervention in refractory CME—role of posterior hyaloid separation and internal limiting membrane peeling. Ocul Immunol Inflamm. 2008;16:209–10.

    Article  PubMed  Google Scholar 

  76. Garweg JG, Becker M, Lommatzsch A, Bartz-Schmidt KU. Update on vitrectomy for pediatric uveitis. Klin Monbl Augenheilkd. 2007;224:538–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, USA

    Raquel Goldhardt

  2. Los Angeles, CA, USA

    Bradley Simon Rosen

Authors
  1. Raquel Goldhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bradley Simon Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raquel Goldhardt.

Additional information

This article is part of the Topical Collection on Therapies in Age-Related Macular Degeneration.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldhardt, R., Rosen, B.S. Uveitic Macular Edema: Treatment Update. Curr Ophthalmol Rep 4, 30–37 (2016). https://doi.org/10.1007/s40135-016-0090-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-016-0090-3

Keywords

Search

Navigation